Indeed, lenvatinib acts by inhibiting multiple receptor tyrosine kinases, including VEGFR1–3, FGFR1–4, PDGFRα, RET and KIT, thereby impairing angiogenesis and tumor proliferation. Here, PDGFRA is linked to neoplasm.